The company is focused on discovering, developing, and commercializing novel cancer therapeutics that target the Bcl-2 cell death regulation pathway. Their research has led to the discovery of GX15-070, a small molecule that selectively reinitiates programmed cell death and may also induce cancer cell self-digestion. Obatoclax has shown promising activity in preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. The company also provides other oncology products, including GMX1777, a small molecule and inhibitor of NAD+ synthesis. With patent protection through 2025, Gemin X Pharmaceuticals is committed to providing patients with cures and relief for various cancer infections.